MRC2 and osteoporosis: Mechanistically speaking, MRC2 is the downstream target gene of miR-23b-3p, a miRNA that inhibits the Wnt/β-catenin signaling pathway during the process of hMSCs osteogenic differentiation by targeting MRC2, thus promoting their osteogenic differentiation and delaying the manifestation of osteoporosis, providing a novel perspective on a potential treatment for osteoporosis [104].